Related posts

Investing in Ozempic Stocks – Unlocking the Stock Price Growth PotentialBest Europe Stocks to Buy: Will 2020 See a European Renaissance?26 Stock Top Picks and 3 ETF (Dec 7-13)
Investor Insights

This summary was created by AI, based on 21 opinions in the last 12 months.

Novo-Nordisk, a global leader in diabetes and obesity drugs, has seen a surge in demand for its weight-loss drug Ozempic. The company has raised its full-year guidance multiple times and expects significant sales growth. However, experts also caution about potential long-term side effects and increasing competition in the weight-loss drug market. While some recommend buying and holding, others advise taking profits due to the stock's rapid rise. Overall, Novo-Nordisk seems to be in a strong position but with potential risks and uncertainties.

Consensus
Mixed
Valuation
Fair Value
COMMENT
Novo-Nordisk

A personal holding since 1995. Their weight-loss drug is the big news now. Remember that after this hype, we'll see if there are any long-term side effects (i.e. the stomach). It's an unproven drug, but could be fine. Meanwhile, they grow their dividend 12% annually. He took profits, because shares ran up so fast. Have the highest R&D to revenues among pharmas. A long-term hold.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Novo and Eli Lilly have both run up, but there's still more room to go, given the strong demand for their weight-loss drug. Insurers will probably pay for these drugs, because without them consumers couldn't afford them. Sure, others are developing their own drugs, but it's not easy. Pfizer just announced it's giving up.

biotechnology / pharmaceutical
premium

It's a Monthly Gems opinion which is available only for Premium members

Curated by Allan Tong since 2019.
99+ opinions with 4.15 rating.

TOP PICK
Novo-Nordisk

You've seen the ads, heard the hype about NVO's Ozempic (and its related Wegovy). As noted above, weight-loss drugs are all the rage, and NVO has attracted as much hype as Taylor Swift's latest album. In mid-October, the Danish company raised full-year guidance in sales and operating profit for the third time this year. NZO expects sales growth of 32-38% up from the prior 27-33%, based on surging popularity for both its drugs in the U.S.

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

Global leader. Recently became Europe's most valuable company by market cap. Diabetes and obesity drugs. Weight loss drug data showing positive cardiac effects as well. Raised guidance to 38% sales growth this year, with operating profit near 46% on the top end. Obesity treatment projected to move from 1M to 48M users by 2030.

Share price above its moving averages, beating S&P, 25% earnings growth rate forecast. Yield is 0.89%.

(Analysts’ price target is $95.28)
biotechnology / pharmaceutical
PARTIAL SELL
Novo-Nordisk

The largest company in Scandinavia. There is and will be lots of competition in weight-loss drugs. NVO has made a fortune through this drug, but their margins will shrink over time as competitors come. If you own this already, take profits, but don't expect NVO to double again.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

Good job marketing Ozempic, taking the US and other countries by storm. Could be a $100B drug class for all participants. Significant weight loss, kidney and heart benefits. Always going to be side effects. Because of its runup, start with a 1/2 position, and then add on any weakness.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

He strongly disagrees with some analysts who say that the new weight-loss drugs won't move the needles of their company stocks. He expects huge demand for these drugs to battle diabetes, which would prevent many other diseases. He sees a lot of runway ahead for LLY and Novo Nordisk.

biotechnology / pharmaceutical
BUY
Novo-Nordisk

Good chart which is indicating momentum. Would recommend buying. 

biotechnology / pharmaceutical
Unspecified
Novo-Nordisk

It has had positive momentum but don't chase it. Two of its drugs are leaders in the space but we don't know the long term effects of these drugs. There are competing products being developed in the weight loss space.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

Recent drug releases have been good for share price appreciation. Currently valued highly. Would wait for share price to fall before investing. Not a good time to buy. 

biotechnology / pharmaceutical
TOP PICK
Novo-Nordisk

Headquartered in Denmark it is the leading global health care company with $32 billion in revenue expected in 2023 and estimates keep growing. It was recently crowned as Europe's most valuable company by market cap. It is the clear leader in diabetes care and obesity drug treatments and produces 50% of the world's insulin. Expected sales growth is 38% this year with operating profit growth of 46%. EPS growth is 25% going forward. 
Buy 4  Hold 1  Sell 1

(Analysts’ price target is $93.75)
biotechnology / pharmaceutical
COMMENT
Novo-Nordisk

Is one of the biggest producers of insulin. Also, now have a hit drug to treat obesity. It's no secret that Western countries have obesity problems. However, a lot of promise has been built in the valuation, based on this drug.

biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

All such drug stocks are going down (oversold) due to inventory worries. But he likes this now.

biotechnology / pharmaceutical
SELL ON STRENGTH
Novo-Nordisk

They stumbled into the hit drug, Ozempic to treat obesity. Nobody knows the long-term effect of this drug yet, but sales are through the roof. NOVO now faces a lot of competition in weight-loss drugs. If you've made a big profit, take profits. 

biotechnology / pharmaceutical
BUY ON WEAKNESS
Novo-Nordisk

Diabetes is not going away. Obesity has made its latest drug popular. Have to ask what are the side effects? Trading at 34-35x forward PE, with a 25%+ growth rate. PEG of 1.6x is not cheap, but not expensive. Overbought. He'd like to see it at the 50- or 200-day MA, around $170-175.

biotechnology / pharmaceutical
Showing 1 to 15 of 121 entries

Novo-Nordisk(NVO-N) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 12

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 14

Stockchase rating for Novo-Nordisk is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novo-Nordisk(NVO-N) Frequently Asked Questions

What is Novo-Nordisk stock symbol?

Novo-Nordisk is a American stock, trading under the symbol NVO-N on the New York Stock Exchange (NVO). It is usually referred to as NYSE:NVO or NVO-N

Is Novo-Nordisk a buy or a sell?

In the last year, 14 stock analysts published opinions about NVO-N. 12 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novo-Nordisk.

Is Novo-Nordisk a good investment or a top pick?

Novo-Nordisk was recommended as a Top Pick by on . Read the latest stock experts ratings for Novo-Nordisk.

Why is Novo-Nordisk stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novo-Nordisk worth watching?

14 stock analysts on Stockchase covered Novo-Nordisk In the last year. It is a trending stock that is worth watching.

What is Novo-Nordisk stock price?

On 2024-02-29, Novo-Nordisk (NVO-N) stock closed at a price of $119.77.